Consequent and intensified relapse therapy improved survival in pediatric AML: Results of relapse treatment in 379 patients of three consecutive AML-BFM trials

Leukemia

Volumn 24, Issue 8, 2010, Pages 1422-1428

  Sander, A ^a   Zimmermann, M ^a   Dworzak, M ^b   Fleischhack, G ^c   Von Neuhoff, C ^a   Reinhardt, D ^a   Kaspers, G J L ^d   Creutzig, U ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

^c UNIVERSITY OF BONN   (Germany)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

chemotherapy; pediatric acute myeloid leukemia (AML); prognostic factor; relapse; stem cell transplantation

Indexed keywords

CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL FEATURE; CYTOGENETICS; DRUG MEGADOSE; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 77955717025     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.127     Document Type: Article

References (27)

1. Kaspers GJL, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 2005; 19: 2025-2029.
2. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030-2042.
3. Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Benard A, Bordigoni P et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003; 21: 4377-4385.
4. Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 2007; 109: 157-163.
5. Stahnke K, Boos J, Bender-Gotze C, Ritter J, Zimmermann M, Creutzig U. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 1998; 12: 1534-1538.
6. Webb DKH, Wheatley K, Harrison G, Stevens RF, Hann IM. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. Leukemia 1999; 13: 25-31.
7. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
8. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 1999; 107: 69-79.
9. Abrahamsson J, Clausen N, Gustafsson G, Hovi L, Jonmundsson G, Zeller B et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol 2007; 136: 229-236.
10. Creutzig U, Ritter J, Zimmermann M, Schellong G. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. J Clin Oncol 1993; 11: 279-286.
11. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001; 19: 2705-2713.
12. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030-2042.
13. Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor inchildren and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006; 24: 4499-4506.
14. Reinhardt D, Hempel G, Fleischhack G, Schulz A, Boos J, Creutzig U. Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. Klin Padiatr 2002; 214: 188-194.
15. Fleischhack G, Hasan C, Graf N, Mann G, Bode U. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 1998; 102: 647-655.
16. Kaplan EL, Meier P. Nonparametric-estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Löffler H et al. Definition of a standard-risk group in children with AML. Br J Haematol 1999; 104: 630-639.
18. Webb DK, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001; 98: 1714-1720.
19. Goemans BF, Tamminga RY, Corbijn CM, Hahlen K, Kaspers GJ. Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only? Haematologica 2008; 93: 1418-1420.
20. Fagioli F, Zecca M, Locatelli F, Lanino E, Uderzo C, Di Bartolomeo P et al. Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. J Pediatr Hematol Oncol 2008; 30: 575-583.
21. Gassas A, Ishaqi MK, Afzal S, Finkelstein-Shechter T, Dupuis A, Doyle J. A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center. Bone Marrow Transplant 2008; 41: 941-945.
22. Godder K, Eapen M, Laver JH, Zhang MJ, Camitta BM, Wayne AS et al. Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis. J Clin Oncol 2004; 22: 3798-3804.
23. Shaw BE, Russell NH. Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant 2008; 41: 495-503.
24. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405-412.
25. Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 2006; 12: 414-421.
26. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007; 13: 116-123.
27. Michallet M, Tanguy ML, Socie G, Thiebaut A, Belhabri A, Milpied N et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 2000; 108: 400-407.